跳至主要内容
临床试验/EUCTR2012-005489-37-ES
EUCTR2012-005489-37-ES进行中(未招募)1 期

A Phase 3b Open-label, Multicenter, Safety and Efficacy Extension Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B

CSL Behring GmbH0 个研究点目标入组 97 人开始时间: 2014年1月10日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
97

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • ? Male subjects, up to 65 years old
  • ? Participated in a CSL-sponsored rIX-FP (CSL654) study, including study CSL654_3001 or study CSL654_3002.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 30
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 55
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • ? Unwilling to participate in the study for a total of 100 exposure days.
  • ? Currently receiving a therapy not permitted during the study.
  • ? Any issue that, in the opinion of the investigator, would render the subject unsuitable for participation in the study.

研究者

相似试验

A Safety and Efficacy Extension Study of a... | 临床试验